Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pilot Study: Favorable Outcomes with Addition of Topotecan to Busulfan/Melphalan As High-Dose Myeloablative Therapy Followed by Autologous Hematopoietic Cell Transplantation

Joseph Rosenthal, MD, Anna Pawlowska, MD, Jerry Cheng, MD, Steven Kechichian, Debbie Hitt, Mary Suarez, Ni-Chun Tsai, MS MPH, Joycelynne Palmer, PHD

Blood (2012) 120 (21): 4553.

https://doi.org/10.1182/blood.V120.21.4553.4553

Published: 2012

Journal Articles

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Joseph Rosenthal, Jeffrey Wong, Anthony Stein, Dajun Qian, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Sandra H. Thomas, Stephen Forman

Blood (2011) 117 (1): 309–315.

https://doi.org/10.1182/blood-2010-06-288357

Published: 2011

Journal Articles

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, Jeffrey Y. Wong, George Somlo, David Snyder, Margaret O’Donnell, Anthony Stein, Ayurporn Nademanee, Maria Delioukina, Leslie Popplewell, Pablo Parker, Ricardo Spielberger, Firoozeh Sahebi, Chatchada Karanes, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Stephen Forman

Blood (2008) 112 (11): 3271.

https://doi.org/10.1182/blood.V112.11.3271.3271

Published: 2008

Journal Articles

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, MD, Jeffrey Wong, MD, Anthony Stein, MD, Ellen Bolotin, MD, PhD, Chatchada Karanes, MD, Leslie Popplwell, MD, Auayporn Nademanee, MD, Firoozeh Sahebi, MD, Margaret O’Donnell, MD, Maria Delioukina, MD, George Somlo, MD, Anna Pawlowska, MD, Debbie Hitt, RN, Marianna Shakhnovits, MD, Stephen Forman, MD

Blood (2007) 110 (11): 3021.

https://doi.org/10.1182/blood.V110.11.3021.3021

Published: 2007

Journal Articles

High-Dose Therapy (HDT) with Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).

Ellen Bolotin, MD, PhD, Marianna Shakhnovits, M.P.H., PhD, Laurence Cooper, MD, PhD, Dajun Qian, PhD, Debbie Hitt, R.N., Robert Sweetman, MD, Judith Sato, MD, James Miser, MD, Stephen Forman, MD, Joseph Rosenthal, MD

Blood (2005) 106 (11): 5500.

https://doi.org/10.1182/blood.V106.11.5500.5500

Published: 2005

NARROW

Pilot Study: Favorable Outcomes with Addition of Topotecan to Busulfan/Melphalan As High-Dose Myeloablative Therapy Followed by Autologous Hematopoietic Cell Transplantation

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

High-Dose Therapy (HDT) with Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).

Email alerts

ASH Publications

American Society of Hematology

Pilot Study: Favorable Outcomes with Addition of Topotecan to Busulfan/Melphalan As High-Dose Myeloablative Therapy Followed by Autologous Hematopoietic Cell Transplantation

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

High-Dose Therapy (HDT) with Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only